Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maas Biolab, a private pharmaceutical company, has advanced to Phase II of its $2.1 million three-year small business innovation research grant from the National Institute of Neurological Disorders and Stroke for the treatment of amyotrophic lateral sclerosis.
Subscribe to our email newsletter
After successful completion of Phase I established initial Mitogard stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was released by the National Institutes of Health.
According to the company, Phase II will complete the preclinical stability, toxicology and pharmacokinetics over the next two years to enable the first human clinical trials for Maas Biolab’s Mitogard intrathecal cyclosporin formula designed for the treatment of amyotrophic lateral sclerosis (ALS).
Jenny Karlsson, director of preclinical development at Maas, said: “The first year’s results show Mitogard intrathecal safety in the therapeutic range, and we look forward with excitement to the second year’s more in-depth toxicology testing.”